News
HanchorBio Participating in the J.P. Morgan Healthcare Conference 2026
HanchorBio Participating in the J.P. Morgan Healthcare Conference 2026 As the holiday season approaches, HanchorBio is kicking off 2026 with active engagement at one of the industry’s most important global healthcare events. HanchorBio is participating in the J.P. Morgan Healthcare Conference 2026, held January 12–15, 2026, in San Francisco. During the conference, Scott Liu, PhD, Founder, Chairman, and […]
Jan 14, 2026
Read more
HanchorBio Reports High Objective Response Rate with HCB101 Combination in Second-Line Gastric Cancer Following ASCO-GI 2026 Poster Presentation
HanchorBio Reports High Objective Response Rate with HCB101 Combination in Second-Line Gastric Cancer Following ASCO-GI 2026 Poster Presentation Mid-dose cohorts demonstrate ~80% ORR when HCB101 is layered on the standard ramucirumab and paclitaxel in second-line gastric cancer. HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today […]
Jan 09, 2026
Read more
HanchorBio 2025 Milestones
HanchorBio 2025 Milestones Patient First, Data Driven. HanchorBio is a clinical-stage biotechnology company advancing differentiated immuno-oncology biologics through its proprietary FBDB™ (Fc-Based Designer Biologics) platform. In 2025, the platform achieved meaningful validation across clinical development, global scientific recognition, intellectual property, and capital markets, marking its transition from platform build-out to clinical execution. FBDB™ Platform Overview […]
Dec 29, 2025
Read more
HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025
HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025 International debut underscores emerging role for macrophage checkpoint therapy in gastric cancer, triple-negative breast cancer, and other hard-to-treat solid tumors [Taipei, Shanghai, and San Francisco | December 12, 2025] –HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and […]
Dec 12, 2025
Read more
HanchorBio Presents First-in-Human Data of HCB101 Monotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma at ASH 2025
HanchorBio Presents First-in-Human Data of HCB101 Monotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma at ASH 2025 Early Phase 1 monotherapy data demonstrate cytopenia-sparing safety, broad pharmacologic window, and early clinical activity in relapsed/refractory non-Hodgkin lymphoma (NHL) HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, presented new first-in-human data […]
Dec 09, 2025
Read more
HanchorBio Presents Preclinical Data at the SITC 2025 on HCB301, a First-in-Class Tri-Specific Immunotherapy Targeting SIRPα-CD47, PD-1/PDL1, and TGFβ
Novel fusion protein shows potent macrophage activation, T-cell restoration, and tumor microenvironment remodeling in preclinical solid tumor models. [Taipei, Shanghai, and San Francisco | November 5, 2025] –HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that the preclinical data on HCB301, a novel […]
Nov 06, 2025
Read more
HanchorBio Invited to Present at the CBA 27th Annual Conference as the Sole Innovative Drug Company Representing Taiwan
Showcase the Broad Therapeutic Potential of HCB101 in Tumor Immunotherapy
*As the only innovative drug company from Taiwan invited to this year’s CBA Annual Conference, HanchorBio took the international stage to present its AI-assisted Structural Engineering on SIRP-alfa fusion biologic for enhancing Safety and Efficacy, marking an important milestone for Taiwan’s biotech industry.”
*This recognition not only strengthens Taiwan’s position in global AI-assisted drug development, but also opens new opportunities for cross-border licensing and collaboration.
Oct 02, 2025
Read more
HanchorBio Receives Third Taiwan TFDA Approval for HCB101 Combination Therapy in Advanced Gastric Cancer
HanchorBio Inc. (7827.TWO), a global clinical-stage biotechnology company developing innovative immunotherapies for oncology and autoimmune diseases, today announced that the Taiwan Food and Drug Administration (TFDA) has approved a third investigator-initiated trial (IIT) evaluating HCB101 in combination with zolbetuximab and chemotherapy for the first-line treatment of patients with HER2-negative, CLDN18.2-positive advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Jul 17, 2025
Read more
HanchorBio Prepares HCB303 Multi-Target Immunotherapy for IND Filing
HCB303 is a novel fusion protein designed to target multiple major immunosuppressive pathways, including PD-L1/PD-1, SIRPα/CD47, and others. By engaging both innate and adaptive immunity, it aims to enhance immune activation within the tumor microenvironment, driving T cell activation, NK cell cytotoxicity, and macrophage phagocytosis. HCB303 is currently in process development, with an IND submission planned by 2026, marking a key milestone in HanchorBio’s multi-target immunotherapy strategy to deliver breakthrough options for patients with refractory cancers.
Jul 11, 2025
Read more
HanchorBio Presents Promising Phase 1 HCB101 Data at ASCO 2025 – Confirmed Partial Response Observed in Solid Tumor and Lymphoma Patients
HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immunotherapies for oncology and autoimmune diseases, today presented interim data from its lead immunotherapy product, HCB101, following its poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 31 – June 4 in Chicago, Illinois. The data, featured in a poster session, demonstrated favorable safety, high CD47 receptor occupancy, and early clinical signs of anti-tumor activity, including confirmed partial response (PR) in patients with head and neck cancer (HNSCC) and marginal zone lymphoma.
Jun 03, 2025
Read more